Active Research Studies: Bladder/Urothelia Cancers

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003) **COHORTS 2-4 AND 6-8 OPEN TO ENROLLMENT**
Study#: 18033 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase 3, Randomized, Open-Label Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
Study#: 18095 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase II open label, study of IMMU-132 in metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1/ PD-L1 based immunotherapy **COHORT 1 CLOSED**
Study#: i2617 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

A Phase II trial of sEphB4-HSA in combination with Anti PD1 Antibody Pembrolizumab (MK-3475) for metastatic urothelial cancer refractory to platinum
Study#: i2658 Phase II
Contact Us: For information about this clinical study, Email Us, or use our form field.

An Open-Label, Randomized, Controlled Phase 3 Study Of Enfortumab Vedotin In Combination With Pembrolizumab With Or Without Chemotherapy, Versus Chemotherapy Alone In Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer
Study#: i2762 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

(42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Study#: 17133 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)
Study#: 19094 Phase III
Contact Us: For information about this clinical study, Email Us, or use our form field.

A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Study#: 20172
Contact Us: For information about this clinical study, Email Us, or use our form field.